The Research Of Human Umbilical Mesenchymal Stem Cells, Protection To The Mice With IgA Nephropathy

ObjectiveExplore the umbilical cord mesenchymal stem cells after intravenousinjection of IgA nephropathy in a mouse model of tail stem cell homing andglomerular mesangial cells and its possible mechanism,to provide a newapproach to stem cell transplantation in the field of kidney diseasetreatmentand theoretical basis.MethodsSPF60male Kunming mice were randomly divided into normal controlgroup，model group，and human umbilical cord mesenchymal stem cell therapygroup (hereinafter referred to as the treatment group). Compound methodusing bovine serum albumin gavage and subcutaneous injection of CCl4andthe combination of LPS to create mice with IgA nephropathy model.14weeksof successful modeling,tail vein injection of human umbilical cordmesenchymal stem cells,7,21,56days, mice were sacrificed material，doneby immunofluorescence staining to determine the modeling and treatment,Masson staining of renal fibrosis, immunohistochemistry of detection of VEGF,CTGF and immunohistochemical detection of CD44determine themesenchymal stem cell homing localization. Western Blot semi-quantitativedetection of VEGF CTGF protein expression to explore the possiblemechanisms using human umbilical cord mesenchymal stem cell treatment ofIgA nephropathy. ResultsAfter the modeling,model group and treated group of mice withproteinuria,25mice had microscopic hematuria，microscopic hematuria in15mice with gross hematuria,which model group,13mice,seven miceappeargross hematuria，treatment group，12mice had microscopic hematuria，8mice had gross hematuria;immunofluorescence showed IgA deposition inmesangial area;stem cell therapy,MASSON staining showed that humanmesenchymal stem cell therapy group fibrosissignificantly compared withnegative control group reduced,urine:24h proteinuria treatment group was(7.15±0.31),(4.87±0.22),(2.95±0.16)g/24h,model group,(12.00±1.38)g/day. Immunohistochemical detection of CD44observed betweenmesenchymal stem cells located in the glomerular and renal interstitialimmunohistochemical qualitative observation that VEGF CTGF in the threegroups,each with a different positive expression,Western blot quantitativeobservation of VEGF CTGF protein in three the group has a differentexpression.ConclusionFrom the above detection it can be drawn between the application ofumbilical cord mesenchymal stem cells,mesangial hyperplasia is reduced,hematuria and proteinuria reduced IgA nephropathy symptoms improvedsignificantly,human umbilical cord mesenchymal stem cells to treat a mousemodel of IgA nephropathyhas a protective effect. Human umbilical cordmesenchymal stem cells into IgA nephropathy mouse model,through theregulation of VEGF and CTGF the expression levels to induceneovascularization generation,to reduce renal fibrosis,repair damagedglomerular mesangial IgA nephropathy a series of symptoms improved,so asto achieve the goal of treatment of IgA nephropathy.